Short answer
Pulmonx Corp (LUNG) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $23M (down 4.6% year over year) with net income of −$10M.
Q2 2026 key financials · XBRL
- Revenue
- $23M
- −4.6% YoY · +10.5% QoQ
- Net income
- −$10M
- +33.6% YoY · +26.2% QoQ
- Operating margin
- -39.8%
- Gross margin
- 78.0%
- EPS (diluted)
- −$0.23
- +39.5% YoY · +30.3% QoQ
Source: XBRL data from the Pulmonx Corp (LUNG) Q2 2026 10-Q on SEC EDGAR. USD.
Pulmonx Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $22.8M, down 4.6% YoY from $23.9M, driven by lower Zephyr Valve volumes and no China sales
- Gross margin 78.0% vs 72.1% YoY, benefiting from geographic mix
- U.S. revenue $14.2M vs $14.7M; international revenue $8.6M vs $9.1M
- Net loss $10.1M vs $15.2M; operating loss $9.1M vs $14.8M
- Cash and equivalents $55.8M; $37.5M outstanding debt; China certificate renewed with shipments expected by early next year
Risk Factors
- No newly triggered risk identified; filing presents existing 10-K risk categories without an explicit “no material changes” statement
- Safety risk: LIBERATE pneumothorax incidence 18–34%, with four treatment-period deaths representing 3.1% of Zephyr Valve patients
- Regulatory risk: Medicare lacks a public coverage policy, leaving reimbursement decisions case-by-case
- Market risk: Zephyr Valve remains the company’s sole therapeutic product and is limited to severe emphysema indications
- Financial risk: Six-month net loss $23.7 million and accumulated deficit $545.3 million as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pulmonx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.